GUOBANG PHARMA LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.45 CNY | -2.19% |
|
+4.74% | -0.63% |
| Apr. 15 | Guobang Pharma Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Jan. 27 | Guobang Pharma Ltd. announces an Equity Buyback for CNY 200 million worth of its shares. | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 16,111 | 14,792 | 9,813 | 9,694 | - |
| Enterprise Value (EV) 1 | 16,111 | 14,792 | 9,813 | 9,694 | 9,694 |
| P/E ratio | 20.9 x | 16 x | 16 x | 9.89 x | 8.06 x |
| Yield | - | 2.27% | 1.71% | 3.61% | 4.24% |
| Capitalization / Revenue | - | 2.59 x | 1.83 x | 1.37 x | 1.2 x |
| EV / Revenue | - | 2.59 x | 1.83 x | 1.37 x | 1.2 x |
| EV / EBITDA | - | 11.3 x | 9.59 x | 8.08 x | 6.59 x |
| EV / FCF | - | 63.8 x | -47.5 x | 52.1 x | 10.7 x |
| FCF Yield | - | 1.57% | -2.11% | 1.92% | 9.37% |
| Price to Book | - | 2.07 x | 1.32 x | 1.17 x | 1.05 x |
| Nbr of stocks (in thousands) | 558,824 | 558,824 | 558,824 | 555,508 | - |
| Reference price 2 | 28.83 | 26.47 | 17.56 | 17.45 | 17.45 |
| Announcement Date | 4/15/22 | 4/9/23 | 4/15/24 | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 5,721 | 5,349 | 7,088 | 8,062 |
| EBITDA 1 | - | 1,313 | 1,023 | 1,200 | 1,471 |
| EBIT 1 | - | 1,053 | 702.3 | 1,142 | 1,394 |
| Operating Margin | - | 18.4% | 13.13% | 16.11% | 17.29% |
| Earnings before Tax (EBT) 1 | - | 1,036 | 697.6 | 932 | 1,187 |
| Net income 1 | 706 | 920.9 | 612.5 | 990.5 | 1,206 |
| Net margin | - | 16.1% | 11.45% | 13.98% | 14.96% |
| EPS 2 | 1.380 | 1.650 | 1.100 | 1.765 | 2.165 |
| Free Cash Flow 1 | - | 231.7 | -206.8 | 186 | 908 |
| FCF margin | - | 4.05% | -3.87% | 2.62% | 11.26% |
| FCF Conversion (EBITDA) | - | 17.65% | - | 15.5% | 61.73% |
| FCF Conversion (Net income) | - | 25.16% | - | 18.78% | 75.28% |
| Dividend per Share 2 | - | 0.6000 | 0.3000 | 0.6300 | 0.7400 |
| Announcement Date | 4/15/22 | 4/9/23 | 4/15/24 | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | 232 | -207 | 186 | 908 |
| ROE (net income / shareholders' equity) | - | 13.7% | 8.43% | 11.8% | 13% |
| ROA (Net income/ Total Assets) | - | 11.1% | 5.91% | 7.5% | 8.9% |
| Assets 1 | - | 8,278 | 10,362 | 13,207 | 13,552 |
| Book Value Per Share 2 | - | 12.80 | 13.30 | 15.00 | 16.60 |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 785 | 724 | 532 | 470 |
| Capex / Sales | - | 13.73% | 13.53% | 7.51% | 5.82% |
| Announcement Date | 4/15/22 | 4/9/23 | 4/15/24 | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
17.45
CNY
Average target price
24
CNY
Spread / Average Target
+37.54%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.63% | 1.34B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 605507 Stock
- Financials Guobang Pharma Ltd.